RxDoctor Payments Data

Kaylin Hauler

Adult Health · Cleveland, OHNPI 1124748538

Payments from drug & device makers

$4,881in general payments, 2019–2025

Across 87 payments — averaging $56.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$704
  • Averitas Pharma Inc.$620
  • Sanofi-aventis U.S. LLC$440
  • Lilly USA, LLC$425
  • Xeris Pharmaceuticals, Inc.$386
  • E.r. Squibb & Sons, L.L.C.$358
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$4,881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,881 in reported general payments places this provider in the 90th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$17,904
Medicare patients
129
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide252$341,983
OzempicSemaglutide185$280,719
JardianceEmpagliflozin101$129,753
TrulicityDulaglutide51$70,249
FarxigaDapagliflozin Propanediol29$25,045
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/717$21,702
Lantus SolostarInsulin Glargine,hum.Rec.Anlog128$16,920
Fiasp FlextouchInsulin Aspart (Niacinamide)17$13,706
Humalog Kwikpen U-100Insulin Lispro39$8,362
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,803
HumalogInsulin Lispro13$5,218
Nano 2nd Gen Pen NeedlePen Needle, Diabetic35$3,561
Novolog FlexpenInsulin Aspart17$2,858
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic21$2,816
Insulin Lispro Kwikpen U-100Insulin Lispro19$2,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$425$417,450316 claims
Novo NordiskOzempic$275$280,719185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,184 adult health providers in Ohio.

Other adult health in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →